Phage Therapy in Lung Infections Caused by Multidrug-resistant Pseudomonas Aeruginosa - A Literature Review

Overview

Journal Eur J Microbiol Immunol (Bp)

Publisher Akademiai Kiado

Specialty Allergy & Immunology

Date 2024 Jan 23

PMID 38261031

Authors

Vincent A Eiselt

Stefan Bereswill

Markus M Heimesaat

Affiliations

Soon will be listed here.

Abstract

Pulmonary infections of patients with cystic fibrosis (CF) or in intensive care units are frequently caused by the Gram-negative opportunistic pathogen Pseudomonas aeruginosa. Since these bacteria are commonly inherently multidrug-resistant (MDR) and hence, antibiotic treatment options are limited, bacteriophages may provide alternative therapeutic and prophylactic measures in the combat of pneumonia caused by P. aeruginosa. This prompted us to perform a comprehensive literature survey of current knowledge regarding effects of phages applied against pulmonary P. aeruginosa infections. The included 23 studies revealed that P. aeruginosa specific phages lyse and eliminate the bacteria even in case of biofilm production in vitro, whereas application to mice and men resulted in mitigated P. aeruginosa induced clinical signs and enhanced survival. Besides distinct host immune responses, no major adverse effects limiting therapeutic and/or prophylactic phage application were noted. However, the immune system and antibiotics generate synergies with phages due to the mutable sensitivity of P. aeruginosa. In conclusion, results summarized in this review provide evidence that phages constitute promising alternative treatment options for lung infections caused by MDR P. aeruginosa. Further studies are needed, however, to underscore the efficacy and safety aspects of phages application to infected patients including immune-compromised individuals.

Citing Articles

Pulmonary Delivery of Antibiotics to the Lungs: Current State and Future Prospects.

Dallal Bashi Y, Mairs R, Murtadha R, Kett V Pharmaceutics. 2025; 17(1).

PMID: 39861758 PMC: 11768398. DOI: 10.3390/pharmaceutics17010111.

Phage Therapy in a Burn Patient Colonized with Extensively Drug-Resistant Responsible for Relapsing Ventilator-Associated Pneumonia and Bacteriemia.

Teney C, Poupelin J, Briot T, Bouar M, Fevre C, Brosset S Viruses. 2024; 16(7).

PMID: 39066242 PMC: 11281479. DOI: 10.3390/v16071080.

References

Chang R, Chow M, Wang Y, Liu C, Hong Q, Morales S . The effects of different doses of inhaled bacteriophage therapy for Pseudomonas aeruginosa pulmonary infections in mice. Clin Microbiol Infect. 2022; 28(7):983-989. DOI: 10.1016/j.cmi.2022.01.006. View

Loc-Carrillo C, Abedon S . Pros and cons of phage therapy. Bacteriophage. 2012; 1(2):111-114. PMC: 3278648. DOI: 10.4161/bact.1.2.14590. View

Iszatt J, Larcombe A, Chan H, Stick S, Garratt L, Kicic A . Phage Therapy for Multi-Drug Resistant Respiratory Tract Infections. Viruses. 2021; 13(9). PMC: 8472870. DOI: 10.3390/v13091809. View

Dan J, Lehman S, Al-Kolla R, Penziner S, Afshar K, Yung G . Development of Host Immune Response to Bacteriophage in a Lung Transplant Recipient on Adjunctive Phage Therapy for a Multidrug-Resistant Pneumonia. J Infect Dis. 2022; 227(3):311-316. PMC: 10152496. DOI: 10.1093/infdis/jiac368. View

Law N, Logan C, Yung G, Furr C, Lehman S, Morales S . Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient. Infection. 2019; 47(4):665-668. DOI: 10.1007/s15010-019-01319-0. View

Yang M, Du C, Gong P, Xia F, Sun C, Feng X . Therapeutic effect of the YH6 phage in a murine hemorrhagic pneumonia model. Res Microbiol. 2015; 166(8):633-43. DOI: 10.1016/j.resmic.2015.07.008. View

Raz A, Serrano A, Hernandez A, Euler C, Fischetti V . Isolation of Phage Lysins That Effectively Kill Pseudomonas aeruginosa in Mouse Models of Lung and Skin Infection. Antimicrob Agents Chemother. 2019; 63(7). PMC: 6591642. DOI: 10.1128/AAC.00024-19. View

Weissfuss C, Wienhold S, Burkle M, Gaborieau B, Bushe J, Behrendt U . Repetitive Exposure to Bacteriophage Cocktails against or Provokes Marginal Humoral Immunity in Naïve Mice. Viruses. 2023; 15(2). PMC: 9964535. DOI: 10.3390/v15020387. View

Chang R, Chen K, Wang J, Wallin M, Britton W, Morales S . Proof-of-Principle Study in a Murine Lung Infection Model of Antipseudomonal Activity of Phage PEV20 in a Dry-Powder Formulation. Antimicrob Agents Chemother. 2017; 62(2). PMC: 5786808. DOI: 10.1128/AAC.01714-17. View

10.

Li M, Chang R, Lin Y, Morales S, Kutter E, Chan H . Phage cocktail powder for Pseudomonas aeruginosa respiratory infections. Int J Pharm. 2021; 596:120200. PMC: 7904610. DOI: 10.1016/j.ijpharm.2021.120200. View

11.

Duplessis C, Warawa J, Lawrenz M, Henry M, Biswas B . Successful Intratracheal Treatment of Phage and Antibiotic Combination Therapy of a Multi-Drug Resistant Murine Model. Antibiotics (Basel). 2021; 10(8). PMC: 8388862. DOI: 10.3390/antibiotics10080946. View

12.

Roach D, Leung C, Henry M, Morello E, Singh D, Di Santo J . Synergy between the Host Immune System and Bacteriophage Is Essential for Successful Phage Therapy against an Acute Respiratory Pathogen. Cell Host Microbe. 2017; 22(1):38-47.e4. DOI: 10.1016/j.chom.2017.06.018. View

13.

Euler C, Raz A, Hernandez A, Serrano A, Xu S, Andersson M . PlyKp104, a Novel Phage Lysin for the Treatment of Klebsiella pneumoniae, Pseudomonas aeruginosa, and Other Gram-Negative ESKAPE Pathogens. Antimicrob Agents Chemother. 2023; 67(5):e0151922. PMC: 10190635. DOI: 10.1128/aac.01519-22. View

14.

Summers W . The strange history of phage therapy. Bacteriophage. 2012; 2(2):130-133. PMC: 3442826. DOI: 10.4161/bact.20757. View

15.

Chow M, Chang R, Li M, Wang Y, Lin Y, Morales S . Pharmacokinetics and Time-Kill Study of Inhaled Antipseudomonal Bacteriophage Therapy in Mice. Antimicrob Agents Chemother. 2020; 65(1). PMC: 7927809. DOI: 10.1128/AAC.01470-20. View

16.

Chen P, Liu Z, Tan X, Wang H, Liang Y, Kong Y . Bacteriophage therapy for empyema caused by carbapenem-resistant Pseudomonas aeruginosa. Biosci Trends. 2022; 16(2):158-162. DOI: 10.5582/bst.2022.01147. View

17.

Alvi I, Asif M, Tabassum R, Aslam R, Abbas Z, Rehman S . RLP, a bacteriophage of the family Podoviridae, rescues mice from bacteremia caused by multi-drug-resistant Pseudomonas aeruginosa. Arch Virol. 2020; 165(6):1289-1297. DOI: 10.1007/s00705-020-04601-x. View

18.

Waters E, Neill D, Kaman B, Sahota J, Clokie M, Winstanley C . Phage therapy is highly effective against chronic lung infections with . Thorax. 2017; 72(7):666-667. PMC: 5520275. DOI: 10.1136/thoraxjnl-2016-209265. View

19.

Fiscarelli E, Rossitto M, Rosati P, Essa N, Crocetta V, Di Giulio A . In Vitro Newly Isolated Environmental Phage Activity against Biofilms Preformed by from Patients with Cystic Fibrosis. Microorganisms. 2021; 9(3). PMC: 7996588. DOI: 10.3390/microorganisms9030478. View

20.

Summers W . Bacteriophage therapy. Annu Rev Microbiol. 2001; 55:437-51. DOI: 10.1146/annurev.micro.55.1.437. View